TL-1A belongs to the TNF superfamily of ligands. It is expressed predominantly in endothelial cells, and to a lesser extent in the placenta, lung, kidney, skeletal muscle, pancreas, small intestine and colon. TL-1A inhibits endothelial cell proliferation and angiogenesis, and has been shown to induce NF-κB activation, caspase activity, and apoptosis in responding cell lines. TL-1A interacts with TNFRSF25/DR3 receptor, but can also bind to a decoy receptor TNFRSF21/DR6. Recombinant Human TL-1A is a 22.0 kDa polypeptide of 194 amino acid residues.
Source:
E.coli
Synonyms:
TNFSF15, VEGI
AA Sequence:
QLRAQGEASV QFQALKGQEF APSHQQVYAP LRADGDKPRA HLTVVRQTPT QHFKNQFPAL HWEHELGLAF TKNRMNYTNK FLLIPESGDY FIYSQVTFRG MTSECSEIRQ AGRPNKPDSI TVVITKVTDS YPEPTQLLMG TKSVCEVGSN WFQPIYLGAM FSLQEGDKLM VNVSDISLVD YTKEDKTFFG AFLL
Purity:
≥ 98% by SDS-PAGE gel and HPLC analyses.
Biological Activity:
Determined by its ability to stimulate IFN-γ production by human PBMC using a concentration range of 10.0-100.0 ng/ml.
Note: Results may vary with PBMC donors.
Note:
1mg will be provided as 2x500μg.
